Pfizer Inc. (NYSE:PFE) Holdings Lowered by Vanguard Capital Wealth Advisors

Vanguard Capital Wealth Advisors lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,805 shares of the biopharmaceutical company’s stock after selling 1,711 shares during the quarter. Vanguard Capital Wealth Advisors’ holdings in Pfizer were worth $282,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. WealthTrust Axiom LLC raised its stake in shares of Pfizer by 19.8% in the 4th quarter. WealthTrust Axiom LLC now owns 121,607 shares of the biopharmaceutical company’s stock worth $3,501,000 after buying an additional 20,112 shares in the last quarter. Certuity LLC lifted its holdings in Pfizer by 81.2% in the 4th quarter. Certuity LLC now owns 64,161 shares of the biopharmaceutical company’s stock valued at $1,847,000 after acquiring an additional 28,752 shares during the last quarter. Kestra Private Wealth Services LLC boosted its position in shares of Pfizer by 3.0% during the 4th quarter. Kestra Private Wealth Services LLC now owns 290,204 shares of the biopharmaceutical company’s stock valued at $8,355,000 after purchasing an additional 8,322 shares in the last quarter. Ledyard National Bank raised its holdings in shares of Pfizer by 3.6% in the 4th quarter. Ledyard National Bank now owns 377,732 shares of the biopharmaceutical company’s stock worth $10,875,000 after purchasing an additional 13,266 shares in the last quarter. Finally, Van ECK Associates Corp lifted its stake in Pfizer by 33.6% during the fourth quarter. Van ECK Associates Corp now owns 12,984,150 shares of the biopharmaceutical company’s stock valued at $373,813,000 after purchasing an additional 3,265,276 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Performance

Pfizer stock traded down $0.03 on Tuesday, hitting $25.61. The company’s stock had a trading volume of 37,889,007 shares, compared to its average volume of 41,962,758. The company has a fifty day moving average price of $26.92 and a 200-day moving average price of $28.31. The firm has a market cap of $145.02 billion, a P/E ratio of 71.50, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the company posted $1.14 EPS. The company’s revenue was down 41.3% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.56%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.